Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Senn develops and manufactures, peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services.

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

“I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts later this year,” said Mr. Azelby. “I look forward to working with Terns’ ...

Nouryon (Amsterdam, the Netherlands) announced the expansion of its Kromasil chromatography-media manufacturing facility in ...

While some orthopedic and spine surgeons are divided on how medications used for weight loss, including Ozempic and Wegovy, will shape the field, it is undeniable that the drugs are playing an ...

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.